- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Chemical Biology
- ACRF Stem Cells and Cancer
- Bioinformatics
- Cancer and Haematology
- Cell Signalling and Cell Death
- Development and Cancer
- Immunology
- Infection and Immunity
- Inflammation
- Molecular Genetics of Cancer
- Molecular Immunology
- Molecular Medicine
- Population Health and Immunity
- Structural Biology
- Systems Biology and Personalised Medicine
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Initiatives
- Partnering opportunities
- Opportunities in platform technologies
- Domain-specific BET bromodomain inhibitors for cancer
- Targeting BFL-1 for the treatment of cancer
- Jointly targeting IGF-1R and IR in cancer
- Soluble CD52 as a therapeutic for inflammatory disease
- TBK inhibitors to treat rheumatoid arthritis
- A novel therapeutic to treat malaria
- Development of a subunit vaccine against malaria
- Eliminating infectious disease via BCL-2 inhibition
- A novel approach to treating Hepatitis B
- Start-up companies
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Research fields
- Bioinformatics
- Cancer biology
- Cell death
- Cell signalling
- Clinical translation
- Computational biology
- Drug discovery
- Epigenetics
- Flow cytometry
- Genomics
- Haematology
- Imaging
- Immunology
- Infection
- Inflammation
- Medicinal chemistry
- Personalised medicine
- Proteomics
- Stem cells
- Structural biology
- Systems biology
- Vaccine development
- People
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Anne Voss
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Edwin Hawkins
- Associate Professor Grant Dewson
- Associate Professor James Murphy
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marnie Blewitt
- Associate Professor Mike Lawrence
- Associate Professor Nicholas Huntington
- Associate Professor Oliver Sieber
- Associate Professor Sandra Nicholson
- Associate Professor Seth Masters
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Dr Andrew Webb
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bob Anderson
- Dr Catheryn O'Brien
- Dr Diana Hansen
- Dr Drew Berry
- Dr Emma Josefsson
- Dr Ethan Goddard-Borger
- Dr Gary Pitt
- Dr Gwo Yaw Ho
- Dr Hélène Jousset Sabroux
- Dr Ian Majewski
- Dr Ian Street
- Dr Jacqui Gulbis
- Dr James Vince
- Dr Jason Tye-Din
- Dr Joanna Groom
- Dr John Wentworth
- Dr Julie Mercer
- Dr Kate Sutherland
- Dr Kelly Rogers
- Dr Ken Pang
- Dr Leanne Robinson
- Dr Leigh Coultas
- Dr Marie-Liesse Asselin-Labat
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Matthew Ritchie
- Dr Melissa Call
- Dr Melissa Davis
- Dr Michael Low
- Dr Misty Jenkins
- Dr Peter Czabotar
- Dr Philippe Bouillet
- Dr Priscilla Auyeung
- Dr Rhys Allan
- Dr Ruth Kluck
- Dr Samar Ojaimi
- Dr Samir Taoudi
- Dr Sant-Rayn Pasricha
- Dr Shalin Naik
- Dr Simon Chatfield
- Dr Stephen Wilcox
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Isabelle Lucet
- Keely Bumsted-O'Brien
- Mr Ian Coulson
- Mr Joel Chibert
- Mr Simon Monard
- Mr Stan Balbata
- Mr Steve Droste
- Ms Carolyn MacDonald
- Ms Samantha Ludolf
- Ms Susanne Williamson
- Ms Wendy Hertan
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Axel Kallies
- Professor Clare Scott
- Professor David Huang
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Li Wu
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Melanie Bahlo
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- Analysis and reporting of whole genome sequencing data from malaria parasites
- Analysis of long read data from the minION, with application to malaria
- Analysis of short tandem repeat markers from whole genome sequencing
- Antibody longevity following Plasmodium vivax infections
- Antigenic diversity of malaria parasites: towards more effective malaria vaccines
- Biogenesis of eosinophil granules
- Biological sequence analysis and genomic variant discovery
- Biology of the unique intra-mitochondrial bacterium Midichloria mitochondrii
- Characterising regulatory T cells in coeliac disease
- Chemical probing to identify effectors of necroptotic cell death
- Computational systems biology of Wnt/cell adhesion signalling in colon cancer
- Controlling apoptotic cell death in cancer
- Deciphering mechanisms of thrombocytopenia (low platelet count) in blood cancers
- Defining molecular signatures of drug resistance and sensitivity
- Designing immunotherapy for brain cancer
- Developing non-invasive methods to monitor kidney transplant rejection
- Discovery and analysis of autoimmune regulators
- Discovery of novel drug combinations for the treatment of bowel cancer
- Drug targets and compounds that block growth of malaria parasites
- Dying to survive: mechanistic insights into human bowel cancer development
- Dynamic discovery of innate immunity through imaging and genomics
- Dysregulation of TNF expression in inflammatory diseases
- Effects of nutrition on immunity and infection in Asia and Africa
- Elucidation of long range methylation structure using nanopore sequencing
- Eosinophil activation
- Eosinophil death
- Eosinophil heterogeneity
- Eosinophil maturation
- Epigenetic regulation of systemic iron homeostasis
- Epigenetic regulation of the immune system
- Explosive cell death and human disease
- Export of malaria virulence proteins during liver infection
- Function of proteins involved in invasion of erythrocytes by malaria parasites
- Functional genomics to improve therapeutic options for rare cancers
- Giardia duodenalis phosphoproteome and protein kinase network
- Harnessing the immune system to target small cell lung cancer
- Home renovations: understanding how Toxoplasma redecorates its host cell
- How do malaria parasites traverse human cells and invade hepatocytes?
- How does the malaria parasite prevent the host liver cell from dying?
- Human monoclonal antibodies against malaria infection
- IL5 signalling in asthma
- Identification of genes critical for the control of chronic infections
- Identification of malaria parasite entry receptors
- Identifying new cell death and inflammatory pathways
- Identifying proteome signatures of high grade glioma for precision medicine
- Insight into the cytotoxic T cell immune synapse
- Investigating apoptosis control in tumour blood vessels
- Investigating brain abnormalities with single cell ‘omics
- Investigating mechanisms of cell death and survival using zebrafish
- Investigating the mechanics of platelet formation
- Investigating the molecular regulation of neovascular eye disease
- Let me in! How Toxoplasma invades human cells
- Long-read sequencing for transcriptome and epigenome analysis
- Machine learning analysis of mutagenesis datasets
- Macro-evolution in cancer
- Mapping human gene mutations affecting anti-malarial drug efficacy
- Mechanism and modulation of K+ channels and membrane transporters
- Mechanisms of disease relapse in acute lymphoblastic leukaemia
- Microbiome analysis using long read nanopore sequencing
- Molecular mechanism underpinning dendritic cell ontogeny and functions
- Molecular mechanisms of innate immune signalling
- Next-generation mucolytics to treat lung diseases
- No sex please, we’re inhibited: searching for drugs to prevent malaria transmission
- Novel biomarkers and mechanisms of antimalarial drug resistance
- Novel real-time, quantitative imaging approaches for studying malaria
- Novel regulators of JAK-STAT signalling in development and disease
- Novel tool for malaria surveillance and intervention
- Optimising serological markers of recent exposure to Plasmodium vivax
- Quantitation of human T cell responses in primary immunodeficiency
- Reconciling intracellular imaging and metastatic behaviour in cancer cells
- Reconstructing the immune response: from molecules to cells to systems
- Role of protein glycosylation in malaria virulence
- Statistical bioinformatic analyses of RNA-seq and ChIP-seq data
- Strategies mammalian cells use to survive without growth factors
- Structural and biochemical studies on Notch signal transduction
- Structural and functional analysis of malaria invasion
- Structural biology and binding studies of BCL-2 family proteins
- Structural studies of invasion processes during malaria infection
- Structural studies of the Plasmodium and Toxoplasma tight-junction complex
- Target identification of potent antimalarial agents
- The role of glycosylation in malaria vaccine design
- Towards a molecular description of plasma cell diversity
- Tracking the spread of malaria in the Asia Pacific region
- Transmembrane control of type I cytokine receptor activation
- Uncovering the roles of long non-coding RNAs in human bowel cancer
- Understanding resistance to apoptotic cell death
- Understanding the common through study of the rare
- Understanding the development of humoral immunity to malaria
- Unravelling cellular circuitry with single cell RNA-seq and CRISPR
- Unravelling the molecular architecture of killer T cells in disease
- Why is interleukin-11 elevated in acute myeloid leukaemia?
- School resources
- Frequently asked questions
- Student profiles
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Vaccine development

Vaccinations are a crucial health intervention to prevent infectious diseases. Our research into how the immune system responds to infections is improving the development of vaccines for globally significant diseases.
Our research into vaccines
Our researchers strive to understand how vaccines trigger immune responses that protect against infections, and develop new vaccines for significant diseases.
Our vaccine research benefits from our researchers’ expertise in infectious diseases and how long-term immunity to infections develops.
An important goal of our research is to develop and test vaccines for malaria.
What are vaccines?
Vaccines are preparations that stimulate protective immune responses against an infection or toxin, using a harmless component, or weakened form of the infectious agent or toxin. For example, most current vaccines stimulate the production of immune proteins called antibodies that specifically neutralise the particular infection or toxin against which the vaccine has been made.
Vaccines can take several forms. They may be:
- Killed microbes of the type that, when alive, cause illness.
- A weakened form of the microbe, or a related microbe, that causes less severe infection.
- A purified component of the microbe, such as a particular protein or carbohydrate, that triggers protective immunity.
Some vaccines also contain substances, called adjuvants, that boost the immune response.
Most vaccines are given as injections, introducing the vaccine into a muscle or a layer of the skin. Some vaccines, particularly for infections that enter the body through the digestive tract, are given orally. The route of delivery of a vaccine influences the characteristics of the protective immunity that is developed.
How are vaccines developed?
There are many pre-clinical stages of research before a vaccine for a disease can be developed. This research addresses questions including:
- Do humans normally develop protective immunity against the infection? This increases the chances of making a successful vaccine.
- Which proteins or carbohydrates in the microbe can immune cells respond to? Are there different versions of these proteins or carbohydrates in the microbe?
- Can the immune-stimulating components of the microbe be packaged in vaccine form, and delivered into experimental systems to stimulate immune responses?
- Do the immune responses prevent subsequent infection with the microbe, and how long does the protection last?
- How can large amounts of the vaccine be prepared in a consistent and cost-efficient way? A vaccine that is labour-intensive to make, or can only be made in small batches, may not be economically feasible.
If a vaccine shows promise in pre-clinical testing, it may enter clinical trials. These involve giving the vaccine to volunteers to test:
- The safety of the vaccine and highest dose tolerated.
- Whether people develop the expected immune changes after being given the vaccine.
- Whether people at risk of infection with the target microbe are protected by the vaccine.
These steps can take many years. If a vaccine is shown to be safe, and beneficial for protecting people against infection, it may be approved by government bodies for clinical use.
Depending on the prevalence and severity of the infection in a community, the vaccine may be recommended:
- For all people, such as measles vaccine, to restrict any transmission of the infection in the community.
- For people who are likely to be exposed to the infection. Cholera vaccinations for travellers visiting parts of the world where this disease is prevalent are an example.
- For people who are at high risk of serious illness caused by an infection that is less severe in most people. For example, people with chronic respiratory diseases are advised to have flu vaccines.
Vaccine safety
All vaccines available for use in humans are thoroughly assessed for safety by independent health authorities and researchers. Vaccines are only approved for use if they are proven to be beneficial in protecting against a potentially serious infection.
In some cases, rare side-effects can occur in a small number of people who receive a vaccine. These are typically less serious, and much less likely than potential side-effects of the infection the vaccine aims to protect against
When a vaccine is recommended for a person, it is because any risk of receiving the vaccine is outweighed by the risk of not being vaccinated and contracting the relevant infection.
The Australian Academy of Science’s The Science of Immunisation booklet provides scientifically valid answers to many of the frequently asked questions about vaccination and vaccine safety.
Switching off immune responses
Usually vaccination refers to treatments that trigger immune responses. Some vaccines are being developed that switch off harmful immune responses.
An example is a nasal insulin spray developed by our researchers that is now in clinical trials for preventing type 1 diabetes in susceptible people. The treatment is being tested for its ability to turn off the harmful immune responses to insulin-secreting pancreatic cells that cause type 1 diabetes.
Researchers:
We have developed the first malaria vaccine that can be tailored to match many different strains of malaria.
What new discoveries and treatments are on the horizon for infectious diseases? Catch up with the discussion from this public talk.
Our researchers have defined for the first time how the size of the immune response is controlled during infection, or in response to vaccination.
We are a member of the Asia Pacific Malaria Elimination Network (APMEN), an international collaborative network working towards eliminating malaria in the Asia-Pacific region.